CD52 and acute lymphoblastic leukemia: Even though these antecedents pointed to a relative effectiveness of anti-CD52 mAb therapy in eliminating MRD in T-ALL, no clear benefits have been observed compared to other available therapies, and no new trials targeting CD52 have been initiated for r/r T-ALL recently.